{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-019645","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.708388+00:00","generated_at":"2026-05-18T06:32:42.485230+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kairos Pharma reports positive safety results from Phase 2 ENV-105 trial in mCRPC","bullets":["No dose-limiting toxicities or unexpected adverse events in first 10 patients.","No Grade 3 or 4 toxicities observed; side effects manageable with standard care.","Phase 2 trial to enroll 100 patients; interim efficacy data expected September 2025.","Company plans to discuss potential pivotal Phase 3 study design with regulators."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-019645","json":"https://secwatch.observer/filing/0001641172-25-019645.json","markdown":"https://secwatch.observer/filing/0001641172-25-019645.md","text":"https://secwatch.observer/filing/0001641172-25-019645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000164117225019645/0001641172-25-019645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000164117225019645/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:32:42.485230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}